Verve names sec­ond PC­SK9 can­di­date; Ex­sci­en­tia picks an­oth­er AI-cre­at­ed mol­e­cule for clin­ic

Boston-based Verve Ther­a­peu­tics has un­veiled its sec­ond PC­SK9-tar­get­ing pro­gram.

The biotech an­nounced the can­di­date, dubbed Verve-102, as part of its wider third-quar­ter fi­nan­cial re­sults. Verve’s sec­ond PC­SK9-tar­get­ing can­di­date is an in vi­vo drug that us­es base edit­ing and is de­liv­ered through the com­pa­ny’s own tech­nol­o­gy known as GalNAc-LNP.

The biotech start­ed the reg­u­la­to­ry sub­mis­sion for the pro­gram ear­li­er this year and plans to start a Phase Ib tri­al to treat pa­tients with the ge­net­ic dis­or­der het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia, or HeFH.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.